North America Nuclear Imaging Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)

The North America Nuclear Imaging Market is segmented By Product (By Equipment and By Radioisotope), By Application (SPECT Applications and PET Applications) and Geography.

North America Nuclear Imaging Industry Overview

North America Nuclear Imaging Market |
Study Period: 2018 - 2028
CAGR: 7 %

Major Players


*Disclaimer: Major Players sorted in no particular order


Need a report that reflects how COVID-19 has impacted this market and its growth?

North America Nuclear Imaging Market Analysis

The North America nuclear imaging market is expected to grow with a CAGR of 7% during the forecasted period. Certain factors that are propelling the growth of the market include technological advancements, increasing diagnostic applications in various diseases, such as cancer and cardiovascular diseases, government support, and a shift from standalone to hybrid modalities. Nuclear imaging has a crucial role in the treatment of several diseases associated with Cardiology, Neurology, orthopedics, etc. Diagnosis through nuclear imaging helps in detecting several diseases such as Cancer. According to the estimates of the American Cancer Society, in 2018, there are around 1,735,350 new cancer cases diagnosed and 609,640 deaths, due to cancer in the United States. The rising prevalence of cancer in the United States will surge the demand for better diagnosis options and further, it will directly trigger the overall market growth.

Moreover, technological advancements in the field of imaging have always been challenging to practitioners in how best to optimize them inpatient care. Over recent years, scientists, researchers, and technologists have been able to bring systems in clinical practice, in which two or even more than two standalone diagnostic imaging modalities are combined. Some of those multimodality imaging systems include PET/CT, SPECT/CT, PET/MRI, and PET/SPECT/CT.

Moreover, the rise in the prevalence of cancer and cardiac ailments is one of the primary drivers for the market. Nuclear medicine is hugely capable of treating cancer and cardiac diseases. There is significant evidence, which proves that diagnosing with nuclear imaging techniques has more impact on patient management for monitoring tumor and also its response to the drug.

North America Nuclear Imaging Industry Segments

Nuclear medicine imaging procedures are non-invasive, with the exception of intravenous injections, and are usually painless medical tests that help physicians diagnose and evaluate medical conditions. These imaging scans use radioactive materials called radiopharmaceuticals or radiotracers. These radiopharmaceuticals are used in diagnosis and therapeutics. They are small substances that contain a radioactive substance that is used in the treatment of cancer, cardiac and neurological disorders.

By Product
By Equipment
By Radioisotope
By Diagnostic Technology
SPECT Radioisotopes
Technetium-99m (TC-99m)
Thallium-201 (TI-201)
Gallium (Ga-67)
Iodine (I-123)
Other SPECT Radioisotopes
PET Radioisotopes
Fluorine-18 (F-18)
Rubidium-82 (RB-82)
Other PET Radioisotopes
By Application
SPECT Applications
Other SPECT Applications
PET Applications
Other PET Applications
North America
United States

Report scope can be customized per your requirements. Click here.

North America Nuclear Imaging Market Trends

This section covers the major market trends shaping the North America Nuclear Imaging Market according to our research experts:

Oncology is Expected to hold the Highest Market Share in PET Applications

The prevalence of various types of cancer has shown a significant rise over the past two decades. According to the statistics of the Lymphoma Research Foundation, each year, more than 100,000 people are diagnosed with lymphoma, and nearly one million people in the United States are living with, or are in remission from, lymphoma. It is the third-most-common cancer in children.

The FDG-PET/CT is more sensitive than a contrast-enhanced CT scan in the staging of several types of lymphoma or in detecting tumor dissemination in several solid cancers, such as breast cancer, lung cancer, and colon cancer.

In the field of oncology, the PET (positron emission tomography) uses FDG (18Fluorine-2-fluoro-2-Deoxy-d-glucose) as the radiopharmaceutical, as it demonstrates the increased metabolism by malignant cells when compared to that of normal cells. Furthermore, there is continuous technological progress in the field of image generation. The introduction of sophisticated software to use PET scan as a biomarker has facilitated new ways to calculate new prognostic markers, such as the metabolic tumor volume (MTV) and the total amount of tumor glycolysis (TLG). The 18F-fluorodeoxyglucose (18F-FDG) has high sensitivity, but it is not tumor specific. This technique can be used for the imaging of lung cancer, lymphoma, head and neck tumors, breast cancer, esophageal cancer, colorectal cancer, and urinary tract tumors. Hence, all the aforementioned technological advancements are expected to drive growth in this segment of the market studied, over the forecast period.

Key trend Nuclear imaging_NA.png

North America Nuclear Imaging Market Competitor Analysis

The North America Nuclear Imaging Market is fragmented competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Bracco Imaging SpA, Cardinal Health Inc., GE Healthcare, Koninklijke Philips NV, Siemens Healthineers, Curium, CMR NAVISCAN (GAMMA MEDICA INC.), Nordion (Canada) Inc., NTP Radioisotopes SOC, Canon Medical Systems Corporation

North America Nuclear Imaging Market Top Players

  1. Bracco Imaging SpA

  2. Cardinal Health Inc.

  3. GE Healthcare

  4. Koninklijke Philips NV

  5. Siemens Healthineers

*Disclaimer: Major Players sorted in no particular order

Competitive Landscape Nuclear imaging.png

North America Nuclear Imaging Market Report - Table of Contents


    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study




    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in Prevalence of Cancer and Cardiac Disorders

      2. 4.2.2 Increase in Technological Advancements

      3. 4.2.3 Growth in Applications of Nuclear Medicine and Imaging

    3. 4.3 Market Restraints

      1. 4.3.1 Regulatory Issues

      2. 4.3.2 Lack of Reimbursement

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry


    1. 5.1 By Product

      1. 5.1.1 By Equipment

      2. 5.1.2 By Radioisotope

        1. By Diagnostic Technology

          1. SPECT Radioisotopes

            1. Technetium-99m (TC-99m)

            2. Thallium-201 (TI-201)

            3. Gallium (Ga-67)

            4. Iodine (I-123)

            5. Other SPECT Radioisotopes

          2. PET Radioisotopes

            1. Fluorine-18 (F-18)

            2. Rubidium-82 (RB-82)

            3. Other PET Radioisotopes

    2. 5.2 By Application

      1. 5.2.1 SPECT Applications

        1. Cardiology

        2. Neurology

        3. Thyroid

        4. Other SPECT Applications

      2. 5.2.2 PET Applications

        1. Oncology

        2. Cardiology

        3. Neurology

        4. Other PET Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. United States

        2. Canada

        3. Mexico


    1. 6.1 Company Profiles

      1. 6.1.1 Bracco Imaging SpA

      2. 6.1.2 Cardinal Health Inc.

      3. 6.1.3 GE Healthcare

      4. 6.1.4 Koninklijke Philips NV

      5. 6.1.5 Siemens Healthineers

      6. 6.1.6 Curium


      8. 6.1.8 Nordion (Canada) Inc.

      9. 6.1.9 NTP Radioisotopes SOC

      10. 6.1.10 Canon Medical Systems Corporation

    2. *List Not Exhaustive

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

North America Nuclear Imaging Market Research FAQs

The North America Nuclear Imaging Market is studied from 2018 - 2028.

The North America Nuclear Imaging Market is growing at a CAGR of 7% over the next 5 years.

Bracco Imaging SpA, Cardinal Health Inc., GE Healthcare, Koninklijke Philips NV, Siemens Healthineers are the major companies operating in North America Nuclear Imaging Market.

North America Nuclear Imaging Industry Reports

In-depth industry statistics and market share insights of the North America Nuclear Imaging sector for 2020, 2021, and 2022. The North America Nuclear Imaging research report provides a comprehensive outlook of the market size and an industry growth forecast for 2023 to 2028. Available to download is a free sample file of the North America Nuclear Imaging report PDF.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!